文献速递间质性肺疾病

糖皮质激素治疗间质性肺疾病急性加重的系统评价

Corticosteroid therapy for treating acute exacerbation of interstitial lung diseases: a systematic review.
PubMed 文献 · Thorax · 2025-02-17

该系统评价检索多个数据库并最终纳入9项研究(总n=18 509),比较高中低剂量激素或非激素治疗对AE-ILD患者临床结局的影响。非IPF的ILD患者中高剂量激素与生存改善及90天死亡率降低相关,而IPF患者中高剂量激素获益不一致、部分研究报告死亡风险增加。

要点

  • 非IPF的AE-ILD患者高剂量激素与生存改善相关(aHR 0.221,95%CI 0.102–0.480)。
  • IPF患者高剂量激素获益不一致,部分研究报告死亡风险增加(OR 1.075)。
  • 证据不一致,需随机对照试验优化AE-ILD激素治疗策略。

核心结论

  • 该综述强调AE-ILD个体化治疗的可能益处,但现有证据不一致,难以作出确定性推荐。

研究设计与样本

  • 遵循PRISMA指南系统检索多个数据库,初检12 454篇文章,经去重和题录筛选后447篇全文审阅,最终纳入9项研究(总n=18 509)。
  • 纳入研究比较AE-ILD治疗中高剂量糖皮质激素与低剂量或非激素干预,结局包括院内和长期死亡率及AE复发。

主要发现

  • 在非IPF的ILD患者中,高剂量激素(泼尼松龙>1.0 mg/kg)与生存改善相关(调整后HR 0.221,95%CI 0.102–0.480,p<0.001)并降低90天死亡率。
  • 高剂量激素早期减量(2周内减量>10%)与院内死亡率降低相关(调整后HR 0.37,95%CI 0.14–0.99)。
  • 前30天累积剂量较高(5185±2414 mg/月 vs 3133±1990 mg/月)与较低复发率相关(调整后HR 0.61,95%CI 0.41–0.90,p=0.02)。
  • 在IPF患者中,高剂量激素获益不一致,部分研究报告死亡风险增加(OR 1.075,95%CI 1.044–1.107,p<0.001)。

临床怎么用

  • 对非IPF的AE-ILD患者可考虑高剂量激素治疗,并关注早期减量及前30天累积剂量对死亡率和复发的影响。
  • 对IPF患者使用高剂量激素需谨慎权衡,因部分研究报告死亡风险增加。

局限性

  • 现有证据不一致,缺乏稳健的文献支持,难以得出确定性结论。
  • 需进一步开展随机对照试验以完善和优化AE-ILD治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute exacerbation of interstitial lung disease (AE-ILD) often results in death and poses significant challenges in clinical management. While corticosteroids are frequently employed, the optimal regimen and their clinical efficacy remain uncertain. To address this knowledge gap, we undertook a systematic review to evaluate the impact of steroid therapy on clinical outcomes in patients experiencing AE-ILD. METHOD: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we systematically searched multiple databases, identifying 12 454 articles. After removing duplicates and screening titles and abstracts, 447 articles were selected for full-text review. Ultimately, nine studies met inclusion criteria, comparing high-dose corticosteroids with low-dose or non-steroidal interventions in treating AE-ILD. Key outcomes included in-hospital and long-term mortality, as well as AE recurrence. RESULTS: Analysis of nine studies (total n=18 509) revealed differential treatment effects based on the ILD subtype. In non-idiopathic pulmonary fibrosis (IPF) ILD, high-dose corticosteroid therapy (>1.0 mg/kg prednisolone) demonstrated improved survival (adjusted HR 0.221, 95% CI 0.102 to 0.480, p<0.001) and reduced 90-day mortality. Early tapering of high-dose corticosteroids (>10% reduction within 2 weeks) reduced in-hospital mortality (adjusted HR 0.37, 95% CI 0.14 to 0.99). Higher cumulative doses in the first 30 days (5185±2414 mg/month vs 3133±1990 mg/month) were associated with lower recurrence rates (adjusted HR 0.61, 95% CI 0.41 to 0.90, p=0.02). In IPF patients, however, high-dose therapy showed inconsistent benefits, with some studies reporting increased mortality risk (OR 1.075, 95% CI 1.044 to 1.107, p<0.001). CONCLUSION: This review emphasises the potential benefits of individualised treatment approaches for AE-ILD but highlights the need for caution in making definitive recommendations. Although high-dose corticosteroids may show promise, particularly in non-IPF cases, the current evidence is inconsistent, and the lack of robust supporting literature makes it difficult to draw firm conclusions. Further research through randomised controlled trials is necessary to refine and optimise therapeutic strategies for AE-ILD.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Srivali N, De Giacomi F, Moua T, et al. Corticosteroid therapy for treating acute exacerbation of interstitial lung diseases: a systematic review. Thorax. 2025. PMID: 39721758. doi:10.1136/thorax-2024-222636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。